February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|What's Hot in HIV Treatment|
|Nutrition and Exercise Tips From HIV Experts at ICAAC 2014|
|A "Bad Year" for HIV Cure Research? Experts Mix Realism and Hope|
|Medicines Patent Pool Signs With 6 Manufacturers to Develop Generic Tenofovir Alafenamide|
|HIV Reservoir Discovered Within Lungs|
|BMS-986001 Bone, Metabolic Data Compare Well to Tenofovir Through 48 Weeks|